GitLab co-founder Sid Sijbrandij has publicly described an effort to take a more active role in treating his osteosarcoma, a bone cancer located in the T5 vertebra of his upper spine. His account combines personal treatment decisions, extensive data collection and the creation of companies intended to make elements of that approach available to other patients.
Sijbrandij says he pursued this path after exhausting standard-of-care options and finding no clinical trial available to him. In his summary of the process, he identifies three broad changes: expanding diagnostic work, creating new treatments, and conducting treatments in parallel. These are his descriptions of an individual medical journey, not clinical guidance or evidence that the same strategy is appropriate for other patients.
A central feature of the project is documentation. Sijbrandij has published a presentation about his cancer journey and points visitors to a recording of a talk delivered through the OpenAI Forum. He also links to a separate data site containing a treatment timeline and an overview of approximately 25 terabytes of material in publicly readable Google Cloud storage. The supplied page does not provide trial results or comparative outcome data that would allow readers to evaluate the effectiveness of particular interventions.
The decision to make such a large record available reflects his broader argument for a more patient-centered medical system. He links his experience with access barriers to a critique of bureaucracy in experimental care. Yet the page's strongest evidentiary value is as a first-person record: it establishes what Sijbrandij says he experienced and built, while leaving medical efficacy, safety and general applicability to be assessed through appropriate research and regulatory processes.
Sijbrandij is also attempting to scale the organizational side of the work through EvenOne Ventures. He describes the companies associated with that initiative as a way to extend the approach beyond his own case. The available summary does not enumerate their products, financing or clinical status, so those details cannot be established from the supplied evidence.
The account sits at an unusual intersection of entrepreneurship and highly personal health care. Company founders are accustomed to moving quickly, gathering data and working across parallel projects; medicine, by contrast, depends on controlled evidence, specialist judgment and safeguards designed around uncertain risks. Sijbrandij's public materials show how he has applied an entrepreneurial model when existing pathways no longer offered him an option. They do not resolve the difficult question of which parts can safely transfer to others.
Readers facing cancer should make treatment decisions with qualified oncology teams. Sijbrandij's disclosures are best understood as a transparent account of one patient's choices and an attempt to build infrastructure around them, rather than as a substitute for medical advice.
